Rafael  Bejar net worth and biography

Rafael Bejar Biography and Net Worth

Dr. Rafael Bejar is an internationally recognized physician scientist with extensive research and clinical experience in the area of hematologic malignancies. Dr. Bejar joined Aptose from UC San Diego where continues to serves as an Associate Professor of Clinical Medicine, cares for patients, and maintains a research laboratory focused on translational studies of myeloid malignancies. At UCSD, he founded the MDS Center of Excellence and led the Hematology Disease Team. There he has directed several clinical studies and served as an advisor for numerous companies including Celgene, Takeda, AbbVie, Astex, Genoptix, Forty Seven, PersImmune, and Daiichi-Sankyo. Outside UCSD, Dr. Bejar sits on the Scientific Advisory Board for the MDS Foundation, is a prior member of the National Comprehensive Cancer Network Guidelines Committee, and has led projects for the International Working Group for MDS. He is frequently invited to speak at national and international meetings and has published articles in a variety of journals including The New England Journal of Medicine, Journal of Clinical Oncology, Leukemia, Blood, and Blood Advances. Dr. Bejar has been board certified in Hematology and Oncology since completing his fellowship at the Dana-Farber Cancer Institute. He completed his internship in Internal Medicine at the University of Chicago followed by his residency at the Brigham and Women’s Hospital in Boston where he later served a Medical Chief Resident and an Instructor in Hematology. He holds an MD degree and Neuroscience PhD from UCSD and a BS in Physics from MIT.

What is Rafael Bejar's net worth?

The estimated net worth of Rafael Bejar is at least $2,790.00 as of November 19th, 2021. Dr. Bejar owns 10,000 shares of Aptose Biosciences stock worth more than $2,790 as of December 22nd. This net worth evaluation does not reflect any other assets that Dr. Bejar may own. Learn More about Rafael Bejar's net worth.

How do I contact Rafael Bejar?

The corporate mailing address for Dr. Bejar and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]. Learn More on Rafael Bejar's contact information.

Has Rafael Bejar been buying or selling shares of Aptose Biosciences?

Rafael Bejar has not been actively trading shares of Aptose Biosciences during the last ninety days. Most recently, on Friday, November 19th, Rafael Bejar bought 666 shares of Aptose Biosciences stock. The stock was acquired at an average cost of $38.40 per share, with a total value of $25,574.40. Learn More on Rafael Bejar's trading history.

Who are Aptose Biosciences' active insiders?

Aptose Biosciences' insider roster includes Rafael Bejar (VP), Denis Burger (Director), Erich Platzer (Director), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder). Learn More on Aptose Biosciences' active insiders.

Are insiders buying or selling shares of Aptose Biosciences?

In the last twelve months, Aptose Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $20,000.00. The most recent insider tranaction occured on November, 25th when CEO William G Rice bought 100,000 shares worth more than $20,000.00. Insiders at Aptose Biosciences own 3.9% of the company. Learn More about insider trades at Aptose Biosciences.

Information on this page was last updated on 11/25/2024.

Rafael Bejar Insider Trading History at Aptose Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Buy666$38.40$25,574.40View SEC Filing Icon  
See Full Table

Rafael Bejar Buying and Selling Activity at Aptose Biosciences

This chart shows Rafael Bejar's buying and selling at Aptose Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aptose Biosciences Company Overview

Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $0.28
Low: $0.21
High: $0.39

50 Day Range

MA: $0.30
Low: $0.17
High: $0.40

2 Week Range

Now: $0.28
Low: $0.13
High: $2.68

Volume

304,802,594 shs

Average Volume

1,745,122 shs

Market Capitalization

$16.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06